Statins for Treatment of Pulmonary Hypertension

  • John L. Faul
  • Peter N. Kao
  • Toshihiko Nishimura
  • Arthur Sung
  • Hong Hu
  • Ronald G. Pearl
Part of the Contemporary Cardiology™ book series (CONCARD)


By virtue of their multiple actions, including anti-inflammatory, antiproliferative, and pro-apoptotic traits and the ability to restore endothelial vasoactive mediator production, statins have been proposed as potential therapies for pulmonary hypertension. In experimental studies in rats with pulmonary hypertension induced either by either monocrotaline or hypoxia, statins have blunted the severity of pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling, sometimes in association with the restoration of the endothelial cell production of nitric oxide. Pending trials that demonstrate the efficacy of statins in pulmonary arterial hypertension in humans, however, the clinical use of statins should be considered investigational.


statins pulmonary hypertension therapy monocrotaline chronic hypoxia experimental pulmonary hypertension simvastatin 


  1. 1.
    Fenton JW, 2nd, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG. Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5(2):115–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Chen Z, Fukutomi T, Zago AC, et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experi\-mental angioplasty without changing plasma lipids. Circulation 2002; 106(1):20–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: Potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003; 167(2):187–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhu JH, Tao QM, Chen JZ, Wang XX, Shang YP. Statins contribute to enhancement of the number and the function of endothelial progenitor cells from peripheral blood. Sheng Li Xue Bao 2004; 56(3):357–64.PubMedGoogle Scholar
  5. 5.
    Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105(25):3017–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108(3):399–405.PubMedGoogle Scholar
  7. 7.
    Szczeklik A, Undas A, Musial J, Gajewski P, Swadzba J, Jankowski M. Antithrombotic actions of statins. Med Sci Monit 2001; 7(6):1381–5.PubMedGoogle Scholar
  8. 8.
    Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103(18):2248–53.PubMedGoogle Scholar
  9. 9.
    Gil-Nunez AC, Villanueva JA. Advantages of lipid-lowering therapy in cerebral ischemia: Role of HMG-CoA reductase inhibitors. Cerebrovasc Dis 2001; 11 (Suppl 1):85–95.PubMedGoogle Scholar
  10. 10.
    Mutanen M, Freese R. Fats, lipids and blood coagulation. Curr Opin Lipidol 2001; 12(1):25–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: Role of microdomains and oxidative stress. Circulation 2004; 109(21 Suppl 1):1134–41.Google Scholar
  12. 12.
    Trochu JN, Mital S, Zhang X, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003; 60(2):250–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Ongini E, Impagnatiello F, Bonazzi A, et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101(22):8497–502.PubMedCrossRefGoogle Scholar
  14. 14.
    Bellosta S, Arnaboldi L, Gerosa L, et al. Statins effect on smooth muscle cell proliferation. Sem Vasc Med 2004; 4(4):347–56.CrossRefGoogle Scholar
  15. 15.
    Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36(1):150–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45(3):173–202.PubMedCrossRefGoogle Scholar
  17. 17.
    Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005; 19(9):1178–80.PubMedGoogle Scholar
  18. 18.
    Dorfmuller P, Humbert M, Capron F, Muller KM. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20(1):9–19.PubMedGoogle Scholar
  19. 19.
    Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67(3):737–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345(5):319–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Trembath RC, Harrison R. Insights into the genetic and molecular basis of primary pulmonary hypertension. Pediatr Res 2003; 53(6):883–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68(1):92–102.PubMedCrossRefGoogle Scholar
  23. 23.
    Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105(14):1672–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Atkinson C, Stewart S, Imamura T, Trembath RC, Morrell NW. Immunolocalisation of BMPR-II and TGF-ss type I and II receptors in primary plexogenic pulmonary hypertension. J Heart Lung Transplant 2001; 20(2):149.PubMedCrossRefGoogle Scholar
  25. 25.
    Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004; 2(3):141–9.PubMedGoogle Scholar
  26. 26.
    Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21(7):1743–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Pammer J, Reinisch C, Kaun C, Tschachler E, Wojta J. Inhibitors of differentiation/DNA binding proteins Id1 and Id3 are regulated by statins in endothelial cells. Endothelium 2004; 11(3–4):175–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Fishman AP. Primary pulmonary arterial hypertension: A look back. J Am Coll Cardiol 2004; 43(12 Suppl S):2S–4S.PubMedCrossRefGoogle Scholar
  29. 29.
    Thompson PD, Moyna NM, White CM, Weber KM, Giri S, Waters DD. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis 2002; 161(2):301–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Puccetti L, Bruni F, Bova G, et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 2001; 11(6):378–87.PubMedGoogle Scholar
  31. 31.
    Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15(2):247–51.PubMedGoogle Scholar
  32. 32.
    Mraiche F, Cena J, Das D, Vollrath B. Effects of statins on vascular function of endothelin-1. Br J Pharmacol 2005; 144(5):715–26.PubMedCrossRefGoogle Scholar
  33. 33.
    Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87(7):616–22.PubMedGoogle Scholar
  34. 34.
    Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6(9):1004–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67(8):863–76.PubMedCrossRefGoogle Scholar
  36. 36.
    Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2000; 162(6):2252–8.PubMedGoogle Scholar
  37. 37.
    Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001; 163(2):498–502.PubMedGoogle Scholar
  38. 38.
    Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166(10):1403–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD. Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med 1998; 158(3):939–50.PubMedGoogle Scholar
  40. 40.
    Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108(13):1640–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Vaszar LT, Nishimura T, Storey JD, et al. Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats. Physiol Genom 2004; 17(2):150–6.CrossRefGoogle Scholar
  42. 42.
    Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285:H938–45.PubMedGoogle Scholar
  43. 43.
    Girgis RE, Ma SF, Ye S, et al. Differential gene expression in chronic hypoxic pulmonary hypertension: Effect of simvastatin treatment. Chest 2005 Dec; 128(6 Suppl):579S.Google Scholar
  44. 44.
    Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40(12):2125–34.Google Scholar
  45. 45.
    Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68(11):1127–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156(18):2085–92.PubMedCrossRefGoogle Scholar
  47. 47.
    Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2(3):483–91.PubMedGoogle Scholar
  48. 48.
    Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19(1):81–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Larner J, Allan G, Kessler C, Reamer P, Gunn R, Huang LC. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol 1998; 9(2–4):127–37.PubMedGoogle Scholar
  50. 50.
    Kao PN. Simvastatin treatment of pulmonary hypertension: An observational case series. Chest 2005; 127(4):1446–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 2002; 86(9):1436–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278(4):313–21.Google Scholar
  53. 53.
    Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101(9):3628–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16(4):508–19.PubMedCrossRefGoogle Scholar
  55. 55.
    Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P. Statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2005; 14(4):287.PubMedCrossRefGoogle Scholar
  56. 56.
    Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28(3):263–75.PubMedCrossRefGoogle Scholar
  57. 57.
    Sochman J, Podzimkova M. Not all statins are alike: Induced rhabdomyolysis on changing from one statin to another one. Int J Cardiol 2005; 99(1):145–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005; 31(5):572–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122(5):1668–73.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Totowa, NJ 2008

Authors and Affiliations

  • John L. Faul
  • Peter N. Kao
  • Toshihiko Nishimura
  • Arthur Sung
  • Hong Hu
  • Ronald G. Pearl

There are no affiliations available

Personalised recommendations